Literature DB >> 28861605

[Sepsis and mortality after severe infections : How epidemiological data confirm results of animal experiments].

A Strangfeld1.   

Abstract

Entities:  

Year:  2017        PMID： 28861605     DOI： 10.1007/s00393-017-0374-5

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  8 in total

1.  GEE for multinomial responses using a local odds ratios parameterization.

Authors:  Anestis Touloumis; Alan Agresti; Maria Kateri
Journal:  Biometrics       Date:  2013-05-31       Impact factor: 2.571

2.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.

Authors:  K J Tracey; Y Fong; D G Hesse; K R Manogue; A T Lee; G C Kuo; S F Lowry; A Cerami
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

3.  Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis.

Authors:  Ping Qiu; Xizhong Cui; Junfeng Sun; Judith Welsh; Charles Natanson; Peter Q Eichacker
Journal:  Crit Care Med       Date:  2013-10       Impact factor: 7.598

4.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

5.  Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease.

Authors:  A Waage; A Halstensen; T Espevik
Journal:  Lancet       Date:  1987-02-14       Impact factor: 79.321

6.  Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

Authors:  A Strangfeld; M Eveslage; M Schneider; H J Bergerhausen; T Klopsch; A Zink; J Listing
Journal:  Ann Rheum Dis       Date:  2011-07-25       Impact factor: 19.103

7.  Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly.

Authors:  James B Galloway; Kimme L Hyrich; Louise K Mercer; William G Dixon; Bo Fu; Andrew P Ustianowski; Kath D Watson; Mark Lunt; Deborah P M Symmons
Journal:  Rheumatology (Oxford)       Date:  2010-07-31       Impact factor: 7.580

8.  Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis.

Authors:  A Richter; J Listing; M Schneider; T Klopsch; A Kapelle; J Kaufmann; A Zink; A Strangfeld
Journal:  Ann Rheum Dis       Date:  2015-11-13       Impact factor: 19.103
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.